No Data
No Data
No Data
No Data
No Data
Needham: Reiterates the Immuneering (IMRX.US) rating, adjusted from buy to buy, with a target price of $15.00.
Needham: Reiterates the Immuneering (IMRX.US) rating, adjusted from buy to buy, with a target price of $15.00.
Zhitong FinanceApr 12 18:40
Needham Reiterates Buy on Immuneering, Maintains $15 Price Target
Needham analyst Ami Fadia reiterates Immuneering with a Buy and maintains $15 price target.
Analyst UpgradesApr 12 18:33
Analysts' Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)
TipRanksApr 12 18:30
Immuneering Presented Preclinical Data At AACR Annual Meeting For Ongoing Phase 2a Clinical Trial Of IMM-1-104 In RAS-Mutated Advanced Or Metastatic Solid Tumors
Globe Newswire- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor
BenzingaApr 10 00:04
IMM-1-104 Is Synergistic With Chemotherapy in Pancreatic Cancer Models
CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting, which the company views as supportive of its ongoing Phase 2a clinical trial of IMM-1-104 in RAS-mutated advanced or metastatic solid tumors.
GlobeNewswireApr 10 00:00
Immuneering(IMRX.US) 10% Shareholder Sells US$1.16 Million in Common Stock
$Immuneering(IMRX.US)$ 10% Shareholder Cormorant Asset Management, LP sold 400K shares of Common Stock on Apr 1, 2024 at an average price of $2.9 for a total value of $1.16 million. This transaction i
Futu NewsApr 4 06:17
No Data
No Data